101 related articles for article (PubMed ID: 9480723)
21. Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus.
Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ
J Clin Pharmacol; 2010 May; 50(5):494-506. PubMed ID: 19934031
[TBL] [Abstract][Full Text] [Related]
22. Depletion of CD8+ T lymphocytes by murine monoclonal CD8 antibodies and restored specific T cell proliferation in vivo in a patient with chronic hepatitis C.
Kiefersauer S; Reiter C; Eisenburg J; Diepolder HM; Rieber EP; Riethmüller G; Gruber R
J Immunol; 1997 Oct; 159(8):4064-71. PubMed ID: 9378996
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of the natural killer cell inhibitory receptor CD94/NKG2A and CD158b on circulating and lesional T cells in patients with chronic plaque psoriasis.
Liao YH; Jee SH; Sheu BC; Huang YL; Tseng MP; Hsu SM; Tsai TF
Br J Dermatol; 2006 Aug; 155(2):318-24. PubMed ID: 16882169
[TBL] [Abstract][Full Text] [Related]
24. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
[TBL] [Abstract][Full Text] [Related]
25. In situ depletion of CD4+ T cells in human skin by Zanolimumab.
Villadsen LS; Skov L; Dam TN; Dagnaes-Hansen F; Rygaard J; Schuurman J; Parren PW; van de Winkel JG; Baadsgaard O
Arch Dermatol Res; 2007 Feb; 298(9):449-55. PubMed ID: 17091277
[TBL] [Abstract][Full Text] [Related]
26. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
Plevy S; Salzberg B; Van Assche G; Regueiro M; Hommes D; Sandborn W; Hanauer S; Targan S; Mayer L; Mahadevan U; Frankel M; Lowder J
Gastroenterology; 2007 Nov; 133(5):1414-22. PubMed ID: 17920064
[TBL] [Abstract][Full Text] [Related]
27. Chronic treatment of mice with low dose anti-CD4 antibody results in a substantial antixenoantibody response and does not deplete CD4 T cells.
Jamali I; Cowdery JS
J Rheumatol; 1992 Aug; 19(8):1321-2. PubMed ID: 1357172
[No Abstract] [Full Text] [Related]
28. Pathogenic role of tonsillar lymphocytes in associated with HSP60/65 in Pustulosis palmaris et plantaris.
Hayashi M; Fujihara K; Beder LB; Yamamoto Y; Hotomi M; Yamanaka N
Auris Nasus Larynx; 2009 Oct; 36(5):578-85. PubMed ID: 19268507
[TBL] [Abstract][Full Text] [Related]
29. Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.
Moreland LW; Haverty TP; Wacholtz MC; Knowles RW; Bucy RP; Heck LW; Koopman WJ
J Rheumatol; 1998 Feb; 25(2):221-8. PubMed ID: 9489810
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study.
Gottlieb AB; Lebwohl M; Shirin S; Sherr A; Gilleaudeau P; Singer G; Solodkina G; Grossman R; Gisoldi E; Phillips S; Neisler HM; Krueger JG
J Am Acad Dermatol; 2000 Oct; 43(4):595-604. PubMed ID: 11004613
[TBL] [Abstract][Full Text] [Related]
31. The role of CD4 and CD8 lymphocytes and macrophages in psoriasis vulgaris.
Cabrijan L; Lipozencić J; Batinac T; Peternel S; Pastar Z
Acta Dermatovenerol Croat; 2009; 17(3):162-5. PubMed ID: 19818213
[TBL] [Abstract][Full Text] [Related]
32. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial.
Bhushan M; Bleiker TO; Ballsdon AE; Allen MH; Sopwith M; Robinson MK; Clarke C; Weller RP; Graham-Brown RA; Keefe M; Barker JN; Griffiths CE
Br J Dermatol; 2002 May; 146(5):824-31. PubMed ID: 12000379
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD4 monoclonal antibody therapy in severe psoriasis.
Morel P; Revillard JP; Nicolas JF; Wijdenes J; Rizova H; Thivolet J
J Autoimmun; 1992 Aug; 5(4):465-77. PubMed ID: 1384529
[TBL] [Abstract][Full Text] [Related]
34. [Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].
Adamicová K; Fetisovová Z; Cingel P; Péc J; Parobeková K; Chromej I
Cesk Patol; 2001 Nov; 37(4):154-7. PubMed ID: 11813632
[TBL] [Abstract][Full Text] [Related]
35. The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin.
Rizova H; Nicolas JF; Morel P; Kanitakis J; Demidem A; Revillard JP; Wijdenes J; Thivolet J; Schmitt D
J Dermatol Sci; 1994 Feb; 7(1):1-13. PubMed ID: 8193079
[TBL] [Abstract][Full Text] [Related]
36. From bench to bedside--translational research in psoriasis.
Prinz JC
J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():1-4. PubMed ID: 20831702
[TBL] [Abstract][Full Text] [Related]
37. CD25(+)CD8(+), CLA(+)CD4(+), CD11a(+) CD4(+), and CD11a(+) CD8(+) T cell counts are elevated in the blood of Brazilian patients with chronic plaque psoriasis.
Porto Ferreira C; Gomes da Silva A; Martins CJ; Da-Cruz AM
Actas Dermosifiliogr; 2011 Jun; 102(5):388-90. PubMed ID: 21419379
[No Abstract] [Full Text] [Related]
38. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action.
Jullien D; Prinz JC; Langley RG; Caro I; Dummer W; Joshi A; Dedrick R; Natta P
Dermatology; 2004; 208(4):297-306. PubMed ID: 15178911
[TBL] [Abstract][Full Text] [Related]
39. Severely photosensitive psoriasis: a phenotypically defined patient subset.
Rutter KJ; Watson RE; Cotterell LF; Brenn T; Griffiths CE; Rhodes LE
J Invest Dermatol; 2009 Dec; 129(12):2861-7. PubMed ID: 19536141
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells.
Herzog C; Walker C; Müller W; Rieber P; Reiter C; Riethmüller G; Wassmer P; Stockinger H; Madic O; Pichler WJ
J Autoimmun; 1989 Oct; 2(5):627-42. PubMed ID: 2572230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
